## Shomik Sengupta Fracs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8787765/publications.pdf

Version: 2024-02-01

147 papers 5,423 citations

34 h-index 70 g-index

157 all docs

157 docs citations

157 times ranked

7384 citing authors

#	Article	IF	CITATIONS
1	Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. Cancer Research, 2006, 66, 3381-3385.	0.4	788
2	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17174-17179.	3.3	723
3	Local excision of rectal cancer. Diseases of the Colon and Rectum, 2001, 44, 1345-1361.	0.7	233
4	Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer, 2005, 104, 511-520.	2.0	231
5	Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube. European Urology, 2019, 75, 564-567.	0.9	215
6	Tumor-Infiltrating Foxp3â^'CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 2075-2081.	3.2	188
7	Does butyrate protect from colorectal cancer?. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 209-218.	1.4	171
8	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
9	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. European Urology, 2020, 78, 893-906.	0.9	112
10	Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer, 2006, 107, 521-529.	2.0	111
11	PREOPERATIVE PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AND VELOCITY ARE STRONG AND INDEPENDENT PREDICTORS OF OUTCOMES FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 174, 2191-2196.	0.2	97
12	EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	0.6	96
13	Renal cell carcinoma: vena caval involvement. BJU International, 2007, 99, 1239-1244.	1.3	94
14	Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Diseases of the Colon and Rectum, 2001, 44, 1759-1765.	0.7	84
15	<pre><scp>U</scp>rological <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand's alignment with the <i><scp>BJU I</scp>nternational</i>: a collaborative success magnified by a supplement journal. BJU International, 2014, 114, 3-5.</pre>	1.3	82
16	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	0.9	80
17	Uroâ€oncology multidisciplinary meetings at an <scp>A</scp> ustralian tertiary referral centre – impact on clinical decisionâ€making and implications for patient inclusion. BJU International, 2014, 114, 50-54.	1.3	70
18	Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer, 2006, 107, 46-53.	2.0	69

#	Article	IF	CITATIONS
19	Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer. Nature Reviews Urology, 2018, 15, 686-692.	1.9	67
20	Use of a computer-controlled bipolar diathermy system in radical prostatectomies and other open urological surgery. ANZ Journal of Surgery, 2001, 71, 538-540.	0.3	62
21	The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer, 2006, 106, 304-312.	2.0	60
22	Impact of Patient Age at Treatment on Outcome Following Radical Retropubic Prostatectomy for Prostate Cancer. Journal of Urology, 2006, 175, 952-957.	0.2	59
23	Psychological Health of Surgeons in a Time of COVID-19. Annals of Surgery, 2023, 277, 50-56.	2.1	59
24	Malignant Hypertension during Cryoablation of an Adrenal Gland Tumor. Journal of Vascular and Interventional Radiology, 2006, 17, 573-575.	0.2	57
25	Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World Journal of Urology, 2019, 37, 667-690.	1.2	52
26	B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology, 2005, 66, 10-14.	0.5	48
27	The management of superficial transitional cell carcinoma of the bladder. Urology, 2006, 67, 48-54.	0.5	45
28	Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 923-926.	1.4	44
29	The role of cystectomy in elderly patients – a multicentre analysis. BJU International, 2015, 116, 73-79.	1.3	41
30	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrateâ€tolerant cells. BJU International, 2018, 121, 971-978.	1.3	39
31	Renal lesions with low R.E.N.A.L nephrometry score are associated with more indolent renal cell carcinomas (RCCs) or benign histology: findings in an Australian cohort. BJU International, 2012, 109, 44-47.	1.3	38
32	Left paraduodenal hernia: Case report and review of the literature. ANZ Journal of Surgery, 2002, 72, 69-71.	0.3	37
33	Association of Abnormal Preoperative Laboratory Values with Survival After Radical Nephrectomy for Clinically Confined Clear Cell Renal Cell Carcinoma. Urology, 2008, 71, 278-282.	0.5	37
34	The effects of nonspecific $\langle scp \rangle HIF \langle  scp \rangle 1 \langle i \rangle \hat{1} \pm \langle  i \rangle$ inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Medicine, 2014, 3, 245-251.	1.3	36
35	Dietary fiber and colorectal neoplasia. Diseases of the Colon and Rectum, 2001, 44, 1016-1033.	0.7	35
36	After radical retropubic prostatectomy †insignificant†prostate cancer has a risk of progression similar to low†risk †significant†cancer. BJU International, 2008, 101, 170-174.	1.3	33

#	Article	IF	CITATIONS
37	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	5.8	33
38	Detectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic Significance. Journal of Urology, 2006, 176, 559-563.	0.2	29
39	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nature Reviews Urology, 2020, 17, 469-481.	1.9	29
40	Transperineal prostate biopsy: a review of technique. Translational Andrology and Urology, 2020, 9, 3009-3017.	0.6	29
41	The Influence of Specific Luminal Factors on the Colonic Epithelium: High-Dose Butyrate and Physical Changes Suppress Early Carcinogenic Events in Rats. Diseases of the Colon and Rectum, 2005, 48, 549-559.	0.7	28
42	Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer, 2006, 106, 2630-2635.	2.0	27
43	Early effects of pharmacological androgen deprivation in human prostate cancer. BJU International, 2007, 99, 60-67.	1.3	27
44	A Systematic Review of Ileal Conduit and Neobladder Outcomes in Primary Bladder Cancer. Urology, 2016, 96, 74-79.	0.5	27
45	Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. BJU International, 2018, 122, 427-433.	1.3	26
46	Incidence and risk factors of venous thromboembolism after pelvic uroâ€oncologic surgery – a single center experience. BJU International, 2016, 117, 50-53.	1.3	25
47	Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review. BJU International, 2017, 119, 10-18.	1.3	23
48	Transitional cell carcinoma growing along an indwelling nephrostomy tube track. BJU International, 1998, 82, 591-591.	1.3	22
49	Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival. Journal of Urology, 2006, 175, 1684-1690.	0.2	22
50	Implementation rates of uroâ€oncology multidisciplinary meeting decisions. BJU International, 2017, 120, 15-20.	1.3	22
51	Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series. BJU International, 2005, 96, 54-57.	1.3	21
52	Rare Expression of KIT and Absence of KIT Mutations in High Grade Renal Cell Carcinoma. Journal of Urology, 2006, 175, 53-56.	0.2	21
53	A New Preoperative Nomogram to Predict Minimal Prostate Cancer: Accuracy and Error Rates Compared to Other Tools to Select Patients for Active Surveillance. Journal of Urology, 2011, 186, 1811-1817.	0.2	20
54	<scp>USANZ</scp> : Timeâ€trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer. BJU International, 2013, 112, 74-82.	1.3	20

#	Article	IF	Citations
55	Impact of Familial and Hereditary Prostate Cancer on Cancer Specific Survival After Radical Retropubic Prostatectomy. Journal of Urology, 2006, 176, 1118-1121.	0.2	18
56	Prediction of Radial Distance of Extraprostatic Extension FromÂPretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.4	18
57	Trends in the use of of nephron-sparing surgery (NSS) at an Australian tertiary referral centre: an analysis of surgical decision-making using the R.E.N.A.L. nephrometry scoring system. BJU International, 2012, 109, 1341-1344.	1.3	18
58	The impact of the global bacille Calmette–Guérin shortage on treatment patterns: populationâ€based data. BJU International, 2018, 121, 169-172.	1.3	17
59	Prostate Specific Antigen Kinetics in the Management of Prostate Cancer. Journal of Urology, 2008, 179, 821-826.	0.2	16
60	Trends in incidence and survival for upper tract urothelial cancer ( <scp>UTUC</scp> ) in the state of Victoria – Australia. BJU International, 2016, 117, 45-49.	1.3	16
61	Survival outcomes of younger men (<Â55Âyears) undergoing radical prostatectomy. Prostate International, 2018, 6, 31-35.	1.2	16
62	Populationâ€based analysis of prostateâ€specific antigen ( <scp>PSA</scp> ) screening in younger men (<55 years) in <scp>A</scp> ustralia. BJU International, 2014, 113, 77-83.	1.3	15
63	BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC Cancer, 2015, 15, 432.	1.1	15
64	Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria. BJU International, 2017, 119, 19-25.	1.3	15
65	Lessons learned in the surgical management of renal cell carcinoma. Urology, 2005, 66, 36-42.	0.5	14
66	Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the <scp>P</scp> rostate <scp>C</scp> ancer <scp>R</scp> egistry. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 247-254.	0.9	14
67	The effect of hypertension and diabetes on the degree of renal function deterioration after unilateral nephrectomy. BJU International, 2011, 108, 1508-1512.	1.3	12
68	Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. Annals of Oncology, 2018, 29, 370-376.	0.6	12
69	A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes. Journal of Contemporary Brachytherapy, 2018, 10, 155-161.	0.4	12
70	Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. BJU International, 2019, 123, 36-42.	1.3	12
71	Surgery for metastatic renal cell cancer. World Journal of Urology, 2005, 23, 155-160.	1.2	11
72	Isolated vasculitis of the bladder. Urology, 2005, 65, 797.	0.5	11

#	Article	IF	CITATIONS
73	Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma. Investigative and Clinical Urology, 2017, 58, 416.	1.0	11
74	Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. Urology, 2006, 68, 810-814.	0.5	10
<b>7</b> 5	Ergonomics perspective for identifying and reducing internal operative flow disruption for laparoscopic urological surgery. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 5043-5056.	1.3	10
76	Prostate cancer screening in Primary Health Care: the current state of affairs. SpringerPlus, 2015, 4, 78.	1.2	9
77	High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 415-421.	0.9	9
78	The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial. World Journal of Urology, 2019, 37, 1111-1116.	1.2	9
79	A narrative review of pelvic lymph node dissection in prostate cancer. Translational Andrology and Urology, 2020, 9, 3049-3055.	0.6	9
80	Single″ayer anatomical reconstruction of the vesicoâ€urethral anastomosis during robotâ€assisted laparoscopic prostatectomy (RALP). BJU International, 2011, 107, 340-343.	1.3	8
81	Use of ultrasound and surgery in adults with acute scrotal pain. ANZ Journal of Surgery, 2011, 81, 366-370.	0.3	8
82	Human error identification for laparoscopic surgery: Development of a motion economy perspective. Applied Ergonomics, 2015, 50, 113-125.	1.7	8
83	The use of tissue fiducial markers in improving the accuracy of post-prostatectomy radiotherapy. Radiation Oncology Journal, 2019, 37, 43-50.	0.7	8
84	Hierarchical task analysis for identification of interrelationships between ergonomic, external disruption, and internal disruption in complex laparoscopic procedures. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 3673-3687.	1.3	8
85	Quality of handwritten surgical operative notes from surgical trainees: a noteworthy issue. ANZ Journal of Surgery, 2019, 89, 176-179.	0.3	8
86	Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. Quality of Life Research, 2021, 30, 345-366.	1.5	8
87	Retroperitoneal lymph node dissection for germ cell tumour. Translational Andrology and Urology, 2020, 9, 3103-3111.	0.6	8
88	Colonic epithelial atrophy induced by a fibre-free diet in rats is reversed by minimal amounts of luminal butyrate, but only in the short term. ANZ Journal of Surgery, 2002, 72, 871-876.	0.3	7
89	The development of prostate cancer despite late onset androgen deficiency. International Journal of Urology, 2005, 12, 847-848.	0.5	7
90	Simple graphic method for estimation of prostate-specific antigen doubling time. Urology, 2006, 67, 408-409.	0.5	7

#	Article	IF	CITATIONS
91	Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population. BJU International, 2012, 109, 48-51.	1.3	7
92	Prostate cancer post-prostatectomy radiotherapy: CT vs MRI for vesico-urethral anastomosis target delineation. Radiotherapy and Oncology, 2017, 125, 113-117.	0.3	7
93	Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital. ANZ Journal of Surgery, 2018, 88, 95-99.	0.3	7
94	Impact of radical prostatectomy on bladder function as demonstrated on urodynamics studyâ€"A systematic review. Neurourology and Urodynamics, 2021, 40, 582-603.	0.8	7
95	RE: THE ACCURACY OF 250 FINE NEEDLE BIOPSIES OF RENAL TUMORS. Journal of Urology, 2005, 174, 2422-2422.	0.2	5
96	Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. Urology, 2006, 68, 94-98.	0.5	5
97	Prospective randomised controlled trial of written supplement to verbal communication of results to patients at the time of flexible cystoscopy. World Journal of Urology, 2018, 36, 883-887.	1.2	5
98	Delays in prostate cancer care within a hospital network in Victoria, Australia. ANZ Journal of Surgery, 2019, 89, 1599-1604.	0.3	5
99	Impact of radiotherapy for localized prostate cancer on bladder function as demonstrated on urodynamics study: A systematic review. Canadian Urological Association Journal, 2021, 15, E664-E671.	0.3	5
100	†Pain†free TRUS B': a phase 3 double†blind placebo†controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography†guided prostate biopsy (ANZUP 1501). BJU International, 2022, 129, 591-600.	1.3	5
101	Impacts of the COVIDâ€19 pandemic on early detection of prostate cancer in Australia. BJU International, 2021, 128, 6-8.	1.3	5
102	Lymphadenectomy with radical cystectomy at an Australian tertiary referral institution: time trends and impact on oncological outcomes. ANZ Journal of Surgery, 2015, 85, 535-539.	0.3	4
103	Diabetes and elevated urea level predict for uretero-ileal stricture after radical cystectomy and ileal conduit formation. Canadian Urological Association Journal, 2017, 11, 88.	0.3	4
104	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. Kidney Cancer, 2018, 2, 123-131.	0.2	4
105	Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial Journal of Clinical Oncology, 2018, 36, TPS531-TPS531.	0.8	4
106	Changing practice of pelvic lymph node dissection in management of primary bladder cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2016, 68, 106-11.	3.9	4
107	Development of a Chronic Colonic Intubation Model in Rats for the Study of Luminal Factors in Colonic Diseases. Diseases of the Colon and Rectum, 2002, 45, 256-263.	0.7	3
108	Early release of pedicles and posterior development of the †Veil of Aphrodite' in roboticâ€assisted laparoscopic prostatectomy (RALP). BJU International, 2010, 106, 1856-1861.	1.3	3

#	Article	IF	CITATIONS
109	Predictors of positive surgical margins at open and robot-assisted laparoscopic radical prostatectomy: a single surgeon series. Journal of Robotic Surgery, 2012, 6, 311-316.	1.0	3
110	Continuous bladder irrigation after transurethral resection of nonâ€muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review. ANZ Journal of Surgery, 2021, 91, 2592-2598.	0.3	3
111	MCP-3 in inflammatory bowel disease Reply. Gut, 2000, 47, 155-155.	6.1	2
112	Gene Expression Profiling of Localized Prostate Cancer: Getting Answers to the Questions That Really Matter. Journal of Clinical Oncology, 2013, 31, 3295-3296.	0.8	2
113	Bladder cancer diagnosis during haematuria investigation – implications for practice guidelines. BJU International, 2017, 119, 53-54.	1.3	2
114	Fiducial markers: can the urologist do better?. World Journal of Urology, 2019, 37, 1281-1287.	1,2	2
115	Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?. Journal of Clinical Oncology, 2015, 33, 415-415.	0.8	2
116	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateâ€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer Journal of Clinical Oncology, 2020, 38, TPS385-TPS385.	0.8	2
117	Is radical prostatectomy of benefit in men with localized prostate cancer?. Nature Clinical Practice Oncology, 2005, 2, 608-609.	4.3	1
118	Use of a barbed suture for continuous urethro-vesical anastomosis during robot-assisted laparoscopic radical prostatectomy. Journal of Robotic Surgery, 2012, 6, 241-242.	1.0	1
119	<scp>BCG</scp> Â+ÂMitomycin trial for highâ€risk nonâ€muscleâ€invasive bladder cancer: progress report and lessons learned. BJU International, 2017, 119, 55-57.	1.3	1
120	Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e412-e419.	0.7	1
121	Survival outcomes in elderly men undergoing radical prostatectomy in Australia. ANZ Journal of Surgery, 2018, 88, E189-E193.	0.3	1
122	Putting guidelines into practice: has the era of perioperative chemotherapy arrived?. Translational Andrology and Urology, 2018, 7, S255-S257.	0.6	1
123	Incorporating intra-lesional injection of mitomycin C in the management algorithm for bladder neck contractures and vesicourethral anastomotic strictures. Journal of Clinical Urology, 2022, 15, 46-53.	0.1	1
124	1403: "Insignificant―Prostate Cancer Treated by Radical Retropubic Prostatectomy has a Risk of Progression Similar to Low-Risk "Significant―Cancer. Journal of Urology, 2007, 177, 462-462.	0.2	1
125	Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and nonâ€malignant prostate epithelial cells. BJU International, 2019, 123, 27-35.	1.3	1
126	Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301) Journal of Clinical Oncology, 2020, 38, TPS602-TPS602.	0.8	1

#	Article	IF	Citations
127	Is nephron-sparing surgery for small renal masses underused?. Nature Reviews Urology, 2006, 3, 412-413.	1.4	O
128	Editorial <scp>C</scp> omment from <scp>D</scp> r <scp>S</scp> engupta and <scp>D</scp> r <scp>W</scp> ebb to <scp>P</scp> elvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. International Journal of Urology, 2013, 20, 412-412.	0.5	0
129	429 IMPACTS OF A URO-ONCOLOGY MULTIDISCIPLINARY MEETING ON CLINICAL DECISION MAKING. Journal of Urology, 2013, 189, .	0.2	O
130	The <scp>A</scp> ustralian and <scp>N</scp> ew <scp>Z</scp> ealand <scp>U</scp> rogenital and <scp>P</scp> rostate ( <scp>ANZUP</scp> ) <scp>C</scp> ancer <scp>T</scp> rials <scp>G</scp> roup – a new coâ€operative cancer trials group in genitourinary oncology. BJU International, 2015, 115, 856-858.	1.3	0
131	Pembrolizumab with ChemoRadiotherapy for Muscle Invasive Bladder Cancer: the ANZUP PCR-MIB trial. Annals of Oncology, 2016, 27, vi294.	0.6	O
132	A Pilot Study: The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E238-E239.	0.4	O
133	Analysis of LDR Outcomes in Clinically Localized Prostate Cancer Incorporating a Significant TURP Cohort: A Community Experience. International Journal of Radiation Oncology Biology Physics, 2017, 99, E265-E266.	0.4	O
134	Differences between PARTICIPANTS AND NON PARTICIPANTS in a randomised controlled trial – LESSONS LEARNT FROM the ENGAGE study of referral for an exercise program in survivors of prostate cancer. BJU International, 2018, 122, 922-923.	1.3	O
135	Correspondence from specialist surgical outpatient clinics to general practitioners. ANZ Journal of Surgery, 2018, 88, 818-819.	0.3	O
136	"Mirror―ureteric colic caused by proximal ureteric calculus in massively hydronephrotic kidney. Urology Case Reports, 2019, 25, 100892.	0.1	O
137	Compliance with followâ€up for patients with stage 1 testicular germ cell tumour. ANZ Journal of Surgery, 2021, 91, 184-186.	0.3	O
138	Exploratory models comparing ethiodized oil-glue and gold fiducials for bladder radiotherapy image-guidance. Physics and Imaging in Radiation Oncology, 2021, 17, 77-83.	1.2	0
139	Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature. ANZ Journal of Surgery, 2021, , .	0.3	O
140	Proximal seminal vesicle displacement and margins for prostate cancer radiotherapy. Journal of Medical Radiation Sciences, 2021, 68, 289-297.	0.8	0
141	Effects of angiotensin-converting enzyme (ACE) inhibitors on the outcomes of patients receiving primary radiotherapy for prostate cancer (PC) Journal of Clinical Oncology, 2013, 31, e16016-e16016.	0.8	O
142	Role of pelvic lymph node dissection in bladder cancer: is it better to do more?. Translational Cancer Research, 2019, 8, S180-S182.	0.4	0
143	Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 185-195.	0.2	0
144	Surgery for urological cancers. Translational Andrology and Urology, 2020, 9, 3007-3008.	0.6	0

#	Article	IF	CITATIONS
145	PD12-08â€∫DEVELOPMENT OF A PATIENT-REPORTED SYMPTOM INDEX FOR USE WITH NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS USING MIXED METHODS. Journal of Urology, 2020, 203, e262.	0.2	0
146	MP72-17 $\hat{a}$ $\in$ fosmotic cytolytic effects of water on cell counts $\hat{a}$ $\in$ "IMPLICATIONS FOR CLINICAL USE WATER IRRIGATION TO REDUCE NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE. Journal of Urology, 2020, 203, .	OF 0.2	0
147	A right anomalous renal artery originating from the superior mesenteric artery. ANZ Journal of Surgery, $0,  ,  .$	0.3	0